|
1
|
Zhang Z, Song Y, Kang J, Duan S, Li Q,
Feng F and Duan J: Epidemiology of patients with central nervous
system infections, mainly neurosurgical patients: A retrospective
study from 2012 to 2019 in a teaching hospital in China. BMC Infect
Dis. 21(826)2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
John CC, Carabin H, Montano SM, Bangirana
P, Zunt JR and Peterson PK: Global research priorities for
infections that affect the nervous system. Nature. 527:S178–S186.
2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Robertson FC, Lepard JR, Mekary RA, Davis
MC, Yunusa I, Gormley WB, Baticulon RE, Mahmud MR, Misra BK,
Rattani A, et al: Epidemiology of central nervous system infectious
diseases: A meta-analysis and systematic review with implications
for neurosurgeons worldwide. J Neurosurg. 130:1107–1126.
2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Giovane RA and Lavender PD: Central
nervous system infections. Prim Care. 45:505–518. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Gajurel BP, Giri S, Rayamajhi S, Khanal N,
Bishowkarma S, Mishra A, Karn R, Rajbhandari R and Ojha R:
Epidemiological and clinical characteristics of central nervous
system infections in a tertiary center: A retrospective study.
Health Sci Rep. 6(e1099)2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
El-Assaad F, Combes V, Grau GER and Jambou
R: Potential efficacy of citicoline as adjunct therapy in treatment
of cerebral malaria. Antimicrob Agents Chemother. 58:602–605.
2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Warsiki E: The effect of citicoline
injections on children with organic brain syndrome caused by
infection. Paediatr Indones. 33:87–94. 2019.
|
|
8
|
Mallah K, Couch C, Borucki DM, Toutonji A,
Alshareef M and Tomlinson S: Anti-inflammatory and neuroprotective
agents in clinical trials for CNS disease and injury: Where do we
go from here? Front Immunol. 11(2021)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Qureshi SS, Gupta JK and Mishra P:
Citicoline: A potential breakthrough in cerebrovascular disorder.
Austi J Pharmacol Ther. 4(1077)2016.
|
|
10
|
Qureshi I and Endres JR: Citicoline: A
novel therapeutic agent with neuroprotective, neuromodulatory, and
neuroregenerative properties. Nat Med J. 2:11–25. 2010.
|
|
11
|
Turana Y, Nathaniel M, Shen R, Ali S and
Aparasu RR: Citicoline and COVID-19-related cognitive and other
neurologic complications. Brain Sci. 12(59)2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Al-Kuraishy HM, Al-Buhadily AK, Al-Gareeb
AI, Alorabi M, Hadi Al-Harcan NAH, El-Bouseary MM and Batiha GES:
Citicoline and COVID-19: Vis-à-vis conjectured. Naunyn
Schmiedebergs Arch Pharmacol. 395:1463–1475. 2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Jambou R, El-Assaad F, Combes V and Grau
GE: Citicoline (CDP-choline): What role in the treatment of
complications of infectious diseases. Int J Biochem Cell Biol.
41:1467–1470. 2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
D'Orlando KJ and Sandage BW Jr: Citicoline
(CDP-choline): Mechanisms of action and effects in ischemic brain
injury. Neurol Res. 17:281–284. 1995.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Samsudin I and Vasikaran SD: Clinical
utility and measurement of procalcitonin. Clin Biochem Rev.
38:59–68. 2017.PubMed/NCBI
|
|
16
|
Vijayan AL, Vanimaya V, Ravindran S,
Saikant R, Lakshmi S, Kartik R and Manoj E: Procalcitonin: A
promising diagnostic marker for sepsis and antibiotic therapy. J
Intensive Care. 5(51)2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Martí-Carvajal AJ, Valli C, Martí-Amarista
CE, Solà I, Martí-Fàbregas J and Bonfill Cosp X: Citicoline for
treating people with acute ischemic stroke. Cochrane Database Syst
Rev. 8(CD013066)2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Dávalos A, Alvarez-Sabín J, Castillo J,
Díez-Tejedor E, Ferro J, Martínez-Vila E, Serena J, Segura T, Cruz
VT, Masjuan J, et al: Citicoline in the treatment of acute
ischaemic stroke: An international, randomised, multicentre,
placebo-controlled study (ICTUS trial). Lancet. 380:349–357.
2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Overgaard K: The effects of citicoline on
acute ischemic stroke: A review. J Stroke Cerebrovas Dis.
23:1764–1769. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Nusanti S, Putri RL and Dearaini D:
Reversible ethambutol-induced optic neuropathy: Report of a rare
case. Universa Med. 41:271–276. 2022.
|
|
21
|
National Center for Biotechnology
Information: PubChem Compound Summary for CID 13804, Citicoline.
National Library of Medicine, Bethesda, MD, 2023.
|
|
22
|
Eid HM, Ali AA, Ali AMA, Eissa EM, Hassan
RM, Abo El-Ela FIA and Hassan AH: Potential use of tailored
citicoline chitosan-coated liposomes for effective wound healing in
diabetic rat model. Int J Nanomedicine. 17:555–575. 2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Poh XY, Loh FK, Friedland JS and Ong CWM:
Neutrophil-mediated immunopathology and matrix metalloproteinases
in central nervous system-tuberculosis. Front Immunol.
12(788976)2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Longhitano L, Tibullo D, Giallongo C,
Lazzarino G, Tartaglia N, Galimberti S, Li Volti G, Palumbo GA and
Liso A: Proteasome inhibitors as a possible therapy for SARS-CoV-2.
Int J Mol Sci. 21(3622)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Manyelo CM, Solomons RS, Walzl G and
Chegou NN: Tuberculous meningitis: Pathogenesis, immune responses,
diagnostic challenges, and the potential of biomarker-based
approaches. J Clin Microbiol. 59:e01771–20. 2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Davis AG, Rohlwink UK, Proust A, Figaji AA
and Wilkinson RJ: The pathogenesis of tuberculous meningitis. J
Leukoc Biol. 105:267–280. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Romero-Adrian TB, Leal-Montiel J,
Fernández G and Valecilo A: Role of cytokines and other factors
involved in the Mycobacterium tuberculosis infection. World
J Immunol. 5:16–50. 2015.
|
|
28
|
Chamorro A, Urra X and Planas AM:
Infection After Acute Ischemic Stroke: A manifestation of
brain-induced immunodepression. Stroke. 38:1097–1103.
2007.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Grabska K, Gromadzka G and Członkowska A:
Infections and ischemic stroke outcome. Neurol Res Int.
2011(691348)2011.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Chavda V, Chaurasia B, Fiorindi A, Umana
GE, Lu B and Montemurro N: Ischemic stroke and SARS-CoV-2
infection: The bidirectional pathology and risk morbidities. Neurol
Int. 14:391–405. 2022.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Dmytriw AA, Dibas M, Phan K, Efendizade A,
Ospel J, Schirmer C, Settecase F, Heran MKS, Kühn AL, Puri AS, et
al: Acute ischaemic stroke associated with SARS-CoV-2 infection in
North America. J Neurol Neurosurg Psychiatry. 93:360–368.
2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Tang S, Liu L, Xie Z, He Y, Zhang Y, Xie
Y, Chen S, Liu Y, Wei Y and Liang Z: Acute Ischemic stroke in
tubercular meningitis patients without conventional vascular risk
factors: A retrospective case control study. J Inflamm Res.
15:6617–6627. 2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Lee HR, Yoo JE, Choi H, Han K, Jung JH,
Park J, Lee H and Shin DW: Tuberculosis and risk of ischemic
stroke: A nationwide cohort study. Stroke. 53:3401–3409.
2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Huaman MA, Henson D, Ticona E, Sterling TR
and Garvy BA: Tuberculosis and cardiovascular disease: Linking the
epidemics. Trop Dis Travel Med Vaccines. 1(10)2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Wang J and Maldonado MA: The
ubiquitin-proteasome system and its role in inflammatory and
autoimmune diseases. Cell Mol Immunol. 3:255–261. 2006.PubMed/NCBI
|
|
36
|
Hemalika DVD: Phospholipase enzymes as
potential biomarker for SARS CoV-2 virus. Int J Sci Res Pub.
11:189–197. 2021.
|
|
37
|
Müller C, Hardt M, Schwudke D, Neuman BW,
Pleschka S and Ziebuhr J: Inhibition of cytosolic phospholipase
A2α impairs an early step of coronavirus replication in
cell culture. J Virol. 92:e01463–17. 2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zweigner J, Jackowski S, Smith SH, van der
Merwe M, Weber JR and Tuomanen EI: Bacterial inhibition of
phosphatidylcholine synthesis triggers apoptosis in the brain. J
Exp Med. 200(99)2004.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Secades JJ and Gareri P: Citicoline:
Pharmacological and clinical review, 2022 update. Rev Neurol.
75:S1–S89. 2022.PubMed/NCBI View Article : Google Scholar : (In English,
Spanish).
|
|
40
|
Channer B, Matt SM, Nickoloff-Bybel EA,
Pappa V, Agarwal Y, Wickman J and Gaskill PJ: Dopamine, immunity,
and disease. Pharmacol Rev. 75:62–158. 2023.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Nolan RA, Muir R, Runner K, Haddad EK and
Gaskill PJ: Role of macrophage dopamine receptors in mediating
cytokine production: Implications for neuroinflammation in the
context of HIV-associated neurocognitive disorders. J Neuroimmune
Pharmacol. 14:134–156. 2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Calderon TM, Williams DW, Lopez L, Eugenin
EA, Cheney L, Gaskill PJ, Veenstra M, Anastos K, Morgello S and
Berman JW: Dopamine increases CD14+CD16+
monocyte transmigration across the blood brain barrier:
Implications for substance abuse and HIV neuropathogenesis. J
Neuroimmune Pharmacol. 12:353–370. 2017.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Sevim Ç, Altinbaş B, Yalçin M, Inan S,
Özyiğit MÖ, Arican İ and Yilmaz MS: Protective effect of
CDP-choline on hypotension and tissue injury in septic shock model.
Ankara Üniv Vet Fak Derg. 64:103–110. 2017.
|
|
44
|
Kobayashi T, Uchino H, Elmér E, Ogihara Y,
Fujita H, Sekine S, Ishida Y, Saiki I, Shibata S and Kawachi A:
Disease outcome and brain metabolomics of cyclophilin-D knockout
mice in sepsis. Int J Mol Sci. 23(961)2022.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Yang Y, Liu Y, Wang Y, Chao Y, Zhang J,
Jia Y, Tie J and Hu D: Regulation of SIRT1 and its roles in
inflammation. Front Immunol. 13(831168)2022.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Bordoni V, Tartaglia E, Sacchi A, Fimia
GM, Cimini E, Casetti R, Notari S, Grassi G, Marchioni L, Bibas M,
et al: The unbalanced p53/SIRT1 axis may impact lymphocyte
homeostasis in COVID-19 patients. Int J Infect Dis. 105:49–53.
2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Hemmat N, Asadzadeh Z, Ahangar NK,
Alemohammad H, Najafzadeh B, Derakhshani A, Baghbanzadeh A, Baghi
HB, Javadrashid D, Najafi S, et al: The roles of signaling pathways
in SARS-CoV-2 infection; Lessons learned from SARS-CoV and
MERS-CoV. Arch Virol. 166:675–696. 2021.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Hurtado O, Hernández-Jiménez M, Zarruk JG,
Cuartero MI, Ballesteros I, Camarero G, Moraga A, Pradillo JM, Moro
MA and Lizasoain I: Citicoline (CDP-choline) increases Sirtuin1
expression concomitant to neuroprotection in experimental stroke. J
Neurochem. 126:819–826. 2013.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Grieb P: Neuroprotective properties of
citicoline: Facts, doubts and unresolved issues. CNS Drugs.
28:185–193. 2014.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Swain SK, Das S and Lenka S: Sudden
sensorineural hearing loss among COVID-19 patients-our experiences
at an Indian teaching hospital. Siriraj Med J. 73:77–83. 2021.
|
|
51
|
Kinoshita J, Iwata N, Maejima T, Kimotsuki
T and Yasuda M: Retinal function and morphology in monkeys with
ethambutol-induced optic neuropathy. Invest Ophthalmol Vis Sci.
53:7052–7062. 2012.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Nusanti S, Sari RI, Siregar NC and Sidik
M: The effect of citicoline on ethambutol optic neuropathy:
Histopathology and immunohistochemistry analysis of retina ganglion
cell damage level in rat model. J Ocul Pharmacol Ther. 38:584–589.
2022.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Yasuhara M and Naito H: Characteristic
actions of CDP-choline on the central nervous system. Curr Ther Res
Clin Exp. 16:346–374. 1974.PubMed/NCBI
|
|
54
|
Faiq MA, Wollstein G, Schuman JS and Chan
KC: Cholinergic nervous system and glaucoma: From basic science to
clinical applications. Prog Retin Eye Res.
72(100767)2019.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Shaukat N, Nisar S, Jan OA, Sajid U,
Mahmood A and Zahid H: The role of citicoline in neuroprotection
and neuro repair in acute stroke. Pak Armed Forces Med J.
73:1161–1164. 2023.
|
|
56
|
Agarwal A, Vishnu VY, Sharma J, Bhatia R,
Garg A, Dwivedi S, Upadhyay A, Goyal V, Singh MB, Gupta A, et al:
Citicoline in acute ischemic stroke: A randomized controlled trial.
PLoS One. 17(e0269224)2022.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Rana D: Evaluation of therapeutic efficacy
of citicoline in acute ischemic stroke patients: A meta analysis.
Int J Med Pharm Res. 4:39–51. 2023.
|
|
58
|
Premi E, Cantoni V, Benussi A, Gilberti N,
Vergani V, Delrio I, Gamba M, Spezi R, Costa A, Padovani A, et al:
Citicoline treatment in acute ischemic stroke: A randomized,
single-blind TMS study. Front Neurol. 13(915362)2022.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Kuryata OV, Kushnir YS, Nedzvetsky VS,
Korsa VV and Tykhomyrov AA: Serum levels of the biomarkers
associated with astrocytosis, neurodegeneration, and demyelination:
Neurological benefits of citicoline treatment of patients with
ischemic stroke and atrial fibrillation. Neurophysiology. 53:2–12.
2021.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Casado A, Secades JJ, Ibarz R, Herdman M
and Brosa M: Cost-effectiveness of citicoline versus conventional
treatment in acute ischemic stroke. Expert Rev Pharmacoecon
Outcomes Res. 8:151–157. 2008.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Ryazhenov VV and Gorokhova SG:
Pharmacoeconomic benefits of citicoline in the treatment of acute
ischemic stroke in Russia. Value Health. 16:A519–A520. 2013.
|
|
62
|
Gareri P, Castagna A, Cotroneo AM,
Putignano S, De Sarro G and Bruni AC: The role of citicoline in
cognitive impairment: Pharmacological characteristics, possible
advantages, and doubts for an old drug with new perspectives. Clin
Interv Aging. 10:1421–1429. 2015.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Putignano S, Gareri P, Castagna A, Cerqua
G, Cervera P, Cotroneo AM, Fiorillo F, Grella R, Lacava R, Maddonni
A, et al: Retrospective and observational study to assess the
efficacy of citicoline in elderly patients suffering from stupor
related to complex geriatric syndrome. Clin Interv Aging.
7:113–118. 2012.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Schauss AG, Somfai-Relle S, Financsek I,
Glavits R, Parent SC, Endres JR, Varga T, Szücs Z and Clewell A:
Single- and repeated-dose oral toxicity studies of citicoline
free-base (choline cytidine 5'-pyrophosphate) in Sprague-Dawley
rats. Int J Toxicol. 28:479–487. 2009.PubMed/NCBI View Article : Google Scholar
|
